Pricing Log in Create free account
Friday 6 November 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.

Revenue
+44.2%
EPS
+1,479.0%
Free cash flow
+93.2%
Total debt
−13.6%

Quarter to September 2026, against a year earlier

15.16 2.08 +15.90%
Market cap
$2.4B
P/E
0.0×
Fwd P/E
−143×
Dividend yield
—
F-score
8/9
Altman Z
0.98
Beneish M
−2.58
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Xeris Biopharma Holdings, Inc. (XERS) EV/EBITDA

Alert me on EV/EBITDA

As of 6 November 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a EV/EBITDA of 54.2×. Over the past ten years it has ranged from 0.0× (June 2025) to 229× (September 2025); the current reading is higher than 96% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.5×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 33.7× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 35.0× 23.51%
Jun 2026 28.3× 32.94%
Mar 2026 21.3× (36.74%)
Dec 2025 33.7× (41.01%)
33 more quarters

Against its own ten years

Low 0.0× High 229×
Ten-year median 0.0×
Current reading's percentile 96

EV/EBITDA against peers

Company EV/EBITDA
PRGO Perrigo Company plc compare n/m
BCRX BioCryst Pharmaceuticals, Inc. compare n/m
ALVO Alvotech compare n/m
TRLV Trulieve Cannabis Corp. compare n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare 0.4×
RGC Regencell Bioscience Holdings Limited compare 1.1×
PBH Prestige Consumer Healthcare Inc. compare 12.4×
XERS Xeris Biopharma Holdings, Inc. 54.2×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.5×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on XERS